4 Healthcare Stock Stories for a Thursday Cure

Pfizer (NYSE:PFE): Closing price $26.83

Pfizer’s partner GlycoMimetics has concluded the enrollment of patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate. This randomized, double-blinded evaluation examined the efficacy, safety and pharmacokinetics of GMI-1070 in hospitalized sickle cell disease patients experiencing vaso-occlusive crisis. GlycoMimetics has enrolled 76 patients from the ¬†ages of 12 through 65 at 22 trial sites in the United States and Canada. The company expects topline data in the second quarter.


Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>